These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 20617418)

  • 1. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
    Mousa SA
    Methods Mol Biol; 2010; 663():181-201. PubMed ID: 20617418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Abrams PJ; Emerson CR
    Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
    Perzborn E; Kubitza D; Misselwitz F
    Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Laux V; Perzborn E; Kubitza D; Misselwitz F
    Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban, an oral direct factor Xa inhibitor.
    Piccini JP; Patel MR; Mahaffey KW; Fox KA; Califf RM
    Expert Opin Investig Drugs; 2008 Jun; 17(6):925-37. PubMed ID: 18491993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J; Sullivan B; Khalabuda M; McBride BF
    J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
    Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban: a new oral factor Xa inhibitor.
    Perzborn E; Roehrig S; Straub A; Kubitza D; Mueck W; Laux V
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):376-81. PubMed ID: 20139357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
    Kakar P; Watson T; Lip GY
    Curr Opin Investig Drugs; 2007 Mar; 8(3):256-65. PubMed ID: 17408122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Turpie AG; Kreutz R; Llau J; Norrving B; Haas S
    Thromb Haemost; 2012 Nov; 108(5):876-86. PubMed ID: 23014816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic and pharmacokinetic basics of rivaroxaban.
    Kreutz R
    Fundam Clin Pharmacol; 2012 Feb; 26(1):27-32. PubMed ID: 21848931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism.
    Chen T; Lam S
    Cardiol Rev; 2009; 17(4):192-7. PubMed ID: 19525681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rivaroxaban (Xarelto): efficacy and safety].
    Rosencher N; Arnaout L; Chabbouh T; Bellamy L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rivaroxaban: mode of action].
    Drouet L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.